Bluejay Diagnostics, INC 8-K filings

Bluejay Diagnostics has increased its authorized shares to 250 million and is working to regain compliance with Nasdaq's minimum bid price requirement.

Bluejay Diagnostics' stockholders voted to approve an increase in authorized shares and the issuance of Class C and Class D warrants at a special meeting on August 21, 2024.

Bluejay Diagnostics has successfully priced an $8.75 million public offering, including common stock or pre-funded warrants, along with Class C and Class D warrants.

Bluejay Diagnostics has announced a 1-for-8 reverse stock split, effective June 20, 2024, to reduce its outstanding shares.

Bluejay Diagnostics has entered into agreements to raise $2 million through the issuance of senior secured notes and common stock to accredited investors.

Bluejay Diagnostics' shareholders approved an increase in authorized shares and a potential reverse stock split at the 2024 Annual Meeting.

Bluejay Diagnostics has terminated its agreement with DLA, resulting in the departure of its Interim CFO, and has designated its CEO as the principal financial officer, while also setting the date for its 2024 annual meeting.

Bluejay Diagnostics has received a notification from Nasdaq that its stock price has fallen below the minimum bid price requirement of $1.00, placing it at risk of delisting.